TY - JOUR
T1 - Should a neck dissection be performed on patients with cN0 adenoid cystic carcinoma? A REFCOR propensity score matching study
AU - Atallah, Sarah
AU - Moya-Plana, Antoine
AU - Malard, Olivier
AU - Poissonnet, Gilles
AU - Fakhry, Nicolas
AU - Bettoni, Jérémie
AU - Gallet, Patrice
AU - Ransy, Pierre
AU - Vergez, Sebastien
AU - De Gabory, Ludovic
AU - Evrard, Diane
AU - Lesnik, Maria
AU - Philouze, Pierre
AU - Bertolus, Chloé
AU - Schultz, Philippe
AU - Morinière, Sylvain
AU - Bastit, Vianney
AU - Righini, Christian A.
AU - Mirghani, Haitham
AU - Jegoux, Franck
AU - Mauvais, Olivier
AU - Biau, Julian
AU - Dufour, Xavier
AU - Bon-Mardion, Nicolas
AU - Brenet, Esteban
AU - Verillaud, Benjamin
AU - Baujat, Bertrand
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Background: Patterns of nodal involvement in adenoid cystic carcinoma (ACC) of the head and neck have not been sufficiently assessed to guide a decision of prophylactic neck dissection (ND). The objective of this study is to analyse the influence of ND on event-free survival (EFS) for patients with cN0 ACC. Patients and methods: A multicentre prospective study was conducted between 2009 and 2018. Patients presenting cN0 non-metastatic ACC on any site, and who received surgery on the tumour, were included. EFS was the main judgement criterion. A comparative survival analysis between the groups that received a ND versus those that did not was performed, using a propensity score. Analyses were carried out using the R software. Results: Between 2009 and 2018, 322 patients with cN0 ACC were included, out of which 58% were female. The average age was 53 years. Tumours were in minor salivary glands in 58% of cases, and 52% had T3/T4 stages. ND was performed on 46% of patients. Out of them, seven had histological lymph node invasion, out of which six had tumour infiltration in the mucosa of oral cavity. After propensity score, the median EFS for N0 patients with ND was 72 months (95% Confidence Interval (CI) [48–81]), compared to 73 months (95% CI [52–85]) for patients without ND (HR = 1.33; 95% CI [0.82–2.16]; p = 0.2). Conclusion: ND of cN0 patients does not provide any benefit on EFS, which suggests that its application on such patients is not necessary.
AB - Background: Patterns of nodal involvement in adenoid cystic carcinoma (ACC) of the head and neck have not been sufficiently assessed to guide a decision of prophylactic neck dissection (ND). The objective of this study is to analyse the influence of ND on event-free survival (EFS) for patients with cN0 ACC. Patients and methods: A multicentre prospective study was conducted between 2009 and 2018. Patients presenting cN0 non-metastatic ACC on any site, and who received surgery on the tumour, were included. EFS was the main judgement criterion. A comparative survival analysis between the groups that received a ND versus those that did not was performed, using a propensity score. Analyses were carried out using the R software. Results: Between 2009 and 2018, 322 patients with cN0 ACC were included, out of which 58% were female. The average age was 53 years. Tumours were in minor salivary glands in 58% of cases, and 52% had T3/T4 stages. ND was performed on 46% of patients. Out of them, seven had histological lymph node invasion, out of which six had tumour infiltration in the mucosa of oral cavity. After propensity score, the median EFS for N0 patients with ND was 72 months (95% Confidence Interval (CI) [48–81]), compared to 73 months (95% CI [52–85]) for patients without ND (HR = 1.33; 95% CI [0.82–2.16]; p = 0.2). Conclusion: ND of cN0 patients does not provide any benefit on EFS, which suggests that its application on such patients is not necessary.
KW - Adenoid cystic carcinoma
KW - Neck dissection
KW - REFCOR
KW - Salivary gland cancer
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85078767893&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2019.12.026
DO - 10.1016/j.ejca.2019.12.026
M3 - Article
C2 - 32008920
AN - SCOPUS:85078767893
SN - 0959-8049
VL - 130
SP - 250
EP - 258
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -